Market Overview

Benzinga's Top Pre-Market Losers

Related NAVB
Navidea Announces Presentation of Study Findings of Manocept Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting
UPDATE: Navidea Biopharma Offers Update on EMA Application For Lymphoseek, Sets Second sNDA PDUFA Target Date Oct. 16th

Navidea Biopharmaceuticals (AMEX: NAVB) dipped 33.33% to $2.34 in the pre-market session. Navidea Biopharmaceuticals received a Complete Response Letter from the Food and Drug Administration regarding its New Drug Application for Lymphoseek®.

United Natural Foods (NASDAQ: UNFI) moved down 6.17% to $56.70 in the pre-market session. United Natural Foods reported a 46% rise in its fourth-quarter profit.

Palo Alto Networks (NASDAQ: PANW) dipped 5.92% to $67.50 in the pre-market session. Palo Alto Networks posted a narrower fiscal fourth-quarter loss.

Sequenom (NASDAQ: SQNM) shares fell 5.37% to $3.70 in the pre-market trading. Sequenom intends to offer $100.0 million aggregate principal amount of Convertible Senior Notes due 2017 in a private offering.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Most Popular

Related Articles (NAVB + PANW)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free